Article (Scientific journals)
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
Hofland, Leo J.; van der Hoek, Joost; Feelders, Richard et al.
2005In European Journal of Endocrinology, 152 (4), p. 645-654
Peer Reviewed verified by ORBi
 

Files


Full Text
EJE-L.Hofland2005.pdf
Publisher postprint (174.51 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adenoma/secretion; Adrenocorticotropic Hormone/secretion; Animals; Gene Expression/drug effects; Glucocorticoids/pharmacology; Humans; Mice; Octreotide/pharmacology; Pituitary Neoplasms/secretion; RNA, Messenger/analysis; Receptors, Somatostatin/genetics/physiology; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin/analogs & derivatives/pharmacology; Tumor Cells, Cultured
Abstract :
[en] Objective: Currently, there is no effective medical treatment for patients with pituitary-dependent Cushing’s disease. A novel somatostatin (SS) analogue, named SOM230, with high binding affinity to SS receptor subtypes sst1, sst2, sst3 and sst5 was recently introduced. We compared the in vitro effects of the sst2-preferring SS analogue octreotide (OCT) and the multi-ligand SOM230 on ACTH release by human and mouse corticotroph tumour cells. Methods: By quantitative RT-PCR the sst subtype expression level was determined in human corticotroph adenomas. In vitro, the inhibitory effect of OCT and SOM230 on ACTH release by dispersed human corticotroph adenoma cells and mouse AtT20 corticotroph adenoma cells was determined. In addition, the influence of dexamethasone on the responsiveness to OCT and SOM230 was studied. Results: Corticotroph adenomas expressed predominantly sst5 mRNA (six out of six adenomas), whereas sst2 mRNA expression was detected at significantly lower levels. In a 72 h incubation with 10 nmol/l SOM230, ACTH release was inhibited in three out of five cultures (range –30 to –40%). Ten nmol/l OCT slightly inhibited ACTH release in only one of five cultures (– 28%). In AtT20 cells, expressing sst2, sst3 and sst5, SOM230 inhibited ACTH secretion with high potency (IC50 0.2 nmol/l). Dexamethasone (10 nmol/l) pre-treatment did not influence the sensitivity of the cells to the inhibitory effect of SOM230, suggesting that sst5 is relatively resistant to negative control by glucocorticoids. Conclusions: The selective expression of sst5 receptors in corticotroph adenomas and the preferential inhibition of ACTH release by human corticotroph adenoma cells by SOM230 in vitro, suggest that SOM230 may have potential in the treatment of patients with pituitary-dependent Cushing’s disease.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Hofland, Leo J.
van der Hoek, Joost
Feelders, Richard
van Aken, Maarten O.
van Koetsveld, Peter M.
Waaijers, Marlijn
Sprij-Mooij, Diana
Bruns, Christian
Weckbecker, Gisbert
de Herder, Wouter W.
Beckers, Albert ;  Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Lamberts, Steven W. J.
Language :
English
Title :
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
Publication date :
April 2005
Journal title :
European Journal of Endocrinology
ISSN :
0804-4643
eISSN :
1479-683X
Publisher :
BioScientifica Ltd, Bristol, United Kingdom
Volume :
152
Issue :
4
Pages :
645-654
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 18 March 2010

Statistics


Number of views
66 (0 by ULiège)
Number of downloads
67 (0 by ULiège)

Scopus citations®
 
239
Scopus citations®
without self-citations
201
OpenCitations
 
202

Bibliography


Similar publications



Contact ORBi